REAL-LIFE DATA OF PAZOPANIB USAGE IN SOFT TISSUE SARCOMA

Abstract: Objective: Soft tissue sarcomas are heterogeneous group of malignancies consisting of more than 50 subtypes. Although it is rare, it is usually resistant to chemotherapy and has a poor prognosis. In this study, we planned to investigate the efficacy, tolerability and side-effect profile of pazopanib in metastatic soft tissue sarcomas. Method-Material: Our study was a single-center retrospective study and included metastatic patients over the age of 18 who were treated with pazopanib. Data of 37 patients were obtained in retrospective medical records. In patients using pazopanib; Tumor location, histological subtype, tumor grade, disease stage, the line at which pazopanib was used, efficacy, tolerability, and side-effect profile of pazopanib were examined. Findings: The mean age of the patients at diagnosis was 49. Pleomorphic sarcoma was the most common subtype. The progression-free survival (PFS) of patients after first-line therapy was 18 weeks. The median overall survival (OS) of the patients was 20 months. The median PFS with pazopanip was 18 weeks. Conclusion: In the study we conducted research in terms of effectiveness and side effects; the use of pazopanib in soft tissue sarcoma was found to be effective in terms of both PFS and OS. Side effects were tolerable and treatable. In our study, a PFS of 32 weeks was obtained in patients with hypothyroidism and at 16 weeks in patients who did not. In this respect, development of hypothyroidism may be a predictive parameter for response.